Regulus Therapeutics (RGLS)
(Delayed Data from NSDQ)
$1.48 USD
+0.02 (1.37%)
Updated Aug 8, 2024 04:00 PM ET
After-Market: $1.50 +0.02 (1.35%) 7:56 PM ET
3-Hold of 5 3
B Value D Growth F Momentum D VGM
Brokerage Reports
0 items in cart
Regulus Therapeutics Inc. [RGLS]
Reports for Purchase
Showing records 221 - 240 ( 273 total )
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Initiation of Alport Natural History Study; First Clinical Catalyst Expected in Q4
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
September and Remaining 2014 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
LIFE SCIENCES AND HEALTH CARE - 2014 LSMAC Day 2
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Emerging Pharmaceuticals - August and 2014 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Reports 2Q?14 EPS; HCV POC Data in 4Q''14
Provider: Brinson Patrick Securities Corporation
Analyst: JAMES C
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Q2 Earnings, Proof of Concept Data Release in Q4, Reiterate OUTPERFORM and $19 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
FDA Grants Orphan Drug Designation To RG-012 for the Treatment of Alport Syndrome
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
FDA Grants Orphan Drug Designation To RG-012 for the Treatment of Alport Syndrome
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
July and 2014 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Granted Patent Strengthens Company?s IP Position on microRNA Therapeutics for HCV; Reiterate OUTPERFORM and $19 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Granted Patent Strengthens Company?s IP Position on microRNA Therapeutics for HCV; Reiterate OUTPERFORM and $19 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
June and 2014 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of May 26
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Emerging Pharmaceuticals - May and 2014 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Initiating coverage with a Market Outperform and $16 Price Target
Provider: Brinson Patrick Securities Corporation
Analyst: JAMES C
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Q1 2014 Update; RG-101/HCV Inhibition Data by YE:14: Reiterate OUTPERFORM and $19 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
April and 2014 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L